From Monoclonal Antibodies for C. difficile Therapy II, no participants (n = 0/69) with a sustained clinical cure through 12 weeks following bezlotoxumab infusion experienced recurrent Clostridioides difficile infection (rCDI) after 9 months (versus actoxumab + bezlotoxumab, n = 2/65; versus placebo, n = 1/34). Bezlotoxumab's efficacy appears to be due to prevention rather than delayed onset of rCDI. Clinical Trials Registration. NCT01513239.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciz1151 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pilot study of infection (CDI) in hospitals, Italy, September to December 2022.
Euro Surveill
January 2025
The members of this group are listed under Acknowledgements.
Background infection (CDI) is a severe infection that needs to be monitored. This infection predominantly occurs in hospitalised patients after antimicrobial treatment, with high mortality in elderly patients.AimWe aimed at estimating the incidence of CDI in Italian hospitals over 4 months in 2022.
View Article and Find Full Text PDFNutritional optimization of fecal microbiota transplantation in humans: a scoping review.
Gut Microbes
December 2025
Medical School, University of Minnesota, Minneapolis, MN, USA.
Diet constitutes a major source of nutrient flow to the gut microbes. As such, it can be used to help shape the gut microbiome. Fecal microbiota transplantation (FMT) is an increasingly promising therapy in disease states beyond recurrent infection, but diet is largely overlooked for its potential to help optimize this therapy.
View Article and Find Full Text PDFFactors for Treatment Failure After Fecal Microbiota Transplantation in Infection.
Microorganisms
December 2024
Division of Gastroenterology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon 22332, Republic of Korea.
Recently, fecal microbiota transplantation (FMT) has been introduced as an effective treatment option for infection (CDI). However, the risk factors associated with FMT treatment failure have not been well demonstrated. Therefore, we aimed to investigate the risk factors of treatment failure or recurrence after FMT for CDI.
View Article and Find Full Text PDFspores are essential for initiation, recurrence and transmission of the disease. The spore surface layers are composed of an outermost exosporium layer that surrounds another proteinaceous layer, the spore coat. These spore surfaces layers are responsible for initial interactions with the host and spore resistance properties contributing to transmission and recurrence of CDI.
View Article and Find Full Text PDFMulti-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection.
Nat Med
January 2025
Vedanta Biosciences, Inc., Cambridge, MA, USA.
Donor-derived fecal microbiota treatments are efficacious in preventing recurrent Clostridioides difficile infection (rCDI), but they have inherently variable quality attributes, are difficult to scale and harbor the risk of pathogen transfer. In contrast, VE303 is a defined consortium of eight purified, clonal bacterial strains developed for prevention of rCDI. In the phase 2 CONSORTIUM study, high-dose VE303 was well tolerated and reduced the odds of rCDI by more than 80% compared to placebo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!